- Home
- TPCS vs FGEN Comparison
TPCS vs FGEN Comparison
Compare TPCS & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPCS
- FGEN
- Stock Information
- Founded
- TPCS 1956
- FGEN 1993
- Country
- TPCS United States
- FGEN United States
- Employees
- TPCS N/A
- FGEN N/A
- Industry
- TPCS Metal Fabrications
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- TPCS Industrials
- FGEN Health Care
- Exchange
- TPCS Nasdaq
- FGEN Nasdaq
- Market Cap
- TPCS 31.5M
- FGEN 34.5M
- IPO Year
- TPCS N/A
- FGEN 2014
- Fundamental
- Price
- TPCS $3.20
- FGEN $0.47
- Analyst Decision
- TPCS
- FGEN
- Analyst Count
- TPCS 0
- FGEN 0
- Target Price
- TPCS N/A
- FGEN N/A
- AVG Volume (30 Days)
- TPCS 25.4K
- FGEN 1.2M
- Earning Date
- TPCS 01-21-2025
- FGEN 02-24-2025
- Dividend Yield
- TPCS N/A
- FGEN N/A
- EPS Growth
- TPCS N/A
- FGEN N/A
- EPS
- TPCS N/A
- FGEN N/A
- Revenue
- TPCS $33,182,059.00
- FGEN $180,015,000.00
- Revenue This Year
- TPCS N/A
- FGEN $21.91
- Revenue Next Year
- TPCS N/A
- FGEN N/A
- P/E Ratio
- TPCS N/A
- FGEN N/A
- Revenue Growth
- TPCS 6.44
- FGEN 16.15
- 52 Week Low
- TPCS $2.85
- FGEN $0.18
- 52 Week High
- TPCS $5.95
- FGEN $2.93
- Technical
- Relative Strength Index (RSI)
- TPCS 46.13
- FGEN 44.58
- Support Level
- TPCS $3.06
- FGEN $0.46
- Resistance Level
- TPCS $3.25
- FGEN $0.51
- Average True Range (ATR)
- TPCS 0.14
- FGEN 0.06
- MACD
- TPCS 0.00
- FGEN -0.02
- Stochastic Oscillator
- TPCS 50.00
- FGEN 15.37
About TPCS TechPrecision Corporation Common stock
Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.